Meeting
2023 ASCO Annual Meeting
Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.
Authors
Kayla Polcari
University of Chicago, Chicago, IL
Kayla Polcari , Grace Keegan , Sarah Sharpe , Olwen Mary Hahn , Stacy Tessler Lindau , Ted Skolarus , Parth K. Modi , Sarah Shubeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Care Delivery
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1546)
DOI
10.1200/JCO.2023.41.16_suppl.1546
Abstract #
1546
Poster Bd #
140
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn
Poster
2022 ASCO Annual Meeting
Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer.
First Author: Elizabeth Joyce
Poster
2022 ASCO Annual Meeting
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA).
First Author: Ryan Tooker